Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 52, n° 3S
page P2 (mars 2005)
Doi : 10.1016/j.jaad.2004.10.024
Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis
 

Richard Langley, MD, Dalhousie University, Halifax, NS, Canada; Craig Leonardi, MD, Central Dermatology, St. Louis, MO, United States; Darryl Toth, MD, Probity Medical Research, Windsor, ON, Canada; Diana Chen, MD, Abbott Laboratories, Abbott Park, IL, United States


 P8
Drs. Langley, Leonardi, and Toth are primary investigators for Abbott Laboratories. Dr. Chen is employed by Abbott Laboratories.
100 percent sponsored by Abbott Laboratories


Top of the page

© 2005  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@